Advertise on podcast: The ReProgram

🎬 EPISODE OVERVIEW Can a younger clock score translate into better health?In Episode 30, I sit down with Dr. Steve Horvath to explore epigenetic clocks, biological-age claims, and his vision for rejuvenation. We discuss why there are so many clocks, what stands between research and patient care, prevention, and why progress may come one organ at a time .👤 ABOUT THE SPEAKER Dr. Steve Horvath is Professor of Medicine and Director of Aging Biology Research at UCLA’s David Geffen School of Medicine. A geroscientist and biostatistician, he developed the influential 2013 multi-tissue DNA methylation clock.Lab profile: https://horvathaginglab.org/ 🔑 KEYWORDS Steve Horvath • Epigenetic Clocks • DNA Methylation • Biological Age • Rejuvenation • Prevention • Aging Biomarkers • Geroscience 📌 KEY TAKEAWAYS • Different aging clocks can produce different results. Horvath argues for transparent reporting across multiple clocks. • Dramatic age-reversal claims deserve scrutiny; a younger test result needs meaningful interpretation. • Horvath sees promise in clinical use, while emphasizing that routine patient care is not there yet. • Rejuvenation is connected to prevention: the aim is to preserve health before disease develops. • A realistic path may focus on individual organs rather than a single treatment for the entire body. 🎙️ THE REPROGRAM PERSPECTIVE Better measurement can sharpen the questions we ask about aging. The next challenge is connecting those measurements to outcomes that matter to people.Our focus: what changed, how reliably was it measured, and what does it mean for health and function? ⏱️ CHAPTERS 00:00 Can we measure and reverse aging? 00:51 Introducing Steve Horvath 01:40 Reinventing a research career 05:28 Why are there so many aging clocks? 07:51 Bringing clocks into clinical practice 09:16 Evaluating age-reversal claims 11:31 Rejuvenation and prevention 14:37 What does rejuvenation mean? 16:26 One organ at a time 18:36 Lifestyle, testing, and perspective 20:57 Closing thoughts 📝 NOTES AND REFERENCES Related papers featured in the edit: 1. Horvath S. DNA methylation age of human tissues and cell types. Genome Biology (2013).https://doi.org/10.1186/gb-2013-14-10-r115 2. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics (2018).https://doi.org/10.1038/s41576-018-0004-3 3. Lu Y et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature (2020).https://doi.org/10.1038/s41586-020-2975-4The Lu study is preclinical mouse research, not evidence of whole-body age reversal in humans. 💬 JOIN THE CONVERSATION What would convince you that an intervention truly rejuvenates: a younger clock score, better organ function, or both? Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcast Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW Why do some animals live so much longer than others—and what can they teach us about healthier human aging?In Episode 29 of The ReProgram, I sit down with Dr. Steve Austad to explore nature’s longevity clues, why women tend to outlive men, and what would count as convincing evidence that an intervention slows aging.We discuss aging “speedometers,” the difference between lifespan and healthspan, the case for funding geroscience, and how to evaluate biological-age claims without losing sight of enjoying life. 👤 ABOUT THE SPEAKER Dr. Steven N. Austad is a Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research at the University of Alabama at Birmingham, and Scientific Director of the American Federation for Aging Research. His research explores the comparative biology of aging, using differences among species to understand longevity and identify potential ways to preserve human health.Official profile: https://www.uab.edu/icar/about/icar-leadership/steven-n-austad-phd 🔑 KEYWORDS Longevity • Comparative Biology • Steve Austad • Healthspan • Aging Rate Indicators • Biological Age • Geroscience • Sex Differences • DunedinPACE 📌 KEY TAKEAWAYS • Long-lived animals offer clues about aging biology and potential directions for human research. • A finding in animals is a starting point; demonstrating a meaningful benefit in people requires further testing. • Measuring biological age and measuring the pace of aging are different questions. A change in a test result alone does not prove that an intervention slows aging. • Healthspan puts the focus on maintaining function and quality of life. • Evaluating longevity claims means asking what was measured, what changed, and whether the evidence supports the conclusion. 🎙️ THE REPROGRAM PERSPECTIVE Nature shows that the pace of aging varies enormously across species. Understanding the biology behind those differences could reveal ways to preserve human health.For The ReProgram, the next step is to connect those clues to rigorous tests: does an intervention produce a reproducible improvement in function, resilience, or healthy years of life? Aging measurements are valuable when they help answer that question. The goal is more time living well, with evidence strong enough to guide our choices. ⏱️ CHAPTERS 00:00 What nature can teach us 00:28 The ReProgram 00:36 Introducing Steve Austad 01:23 Opossums and the origins of an aging scientist 02:44 What is aging? 03:43 Evolution and longevity 04:46 Learning from long-lived animals 07:24 Why women tend to live longer 12:03 What would count as evidence of slower aging? 13:13 From animal findings to human benefits 14:31 Aging clocks versus aging speedometers 18:49 Lifespan and healthspan 19:44 Lightning round: the XPRIZE 21:19 Funding aging research 22:43 Evaluating biological-age claims 24:01 Enjoying life while studying longevity 25:13 Closing thoughts 📝 NOTES AND REFERENCES 1. Austad SN, Kaeberlein M, Miller RA. Aging rate indicators and the search for anti-aging drugs. Frontiers in Science (2026).https://doi.org/10.3389/fsci.2026.1821393 2. Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife (2022);11:e73420.https://doi.org/10.7554/eLife.73420Clarification: DunedinPACE uses DNA methylation to estimate the pace of aging. The on-screen explanation clarifies the interview’s reference to an RNA marker. 3. XPRIZE Healthspan — official competition information:https://www.xprize.org/competitions/healthspan 💬 JOIN THE CONVERSATION What would convince YOU that a treatment truly slows aging: a biological-age test, better physical function, or something else? Tell us which result matters most—and why.If you value longevity science without the hype, subscribe to The ReProgram.https://www.youtube.com/@ReProgramPodcast Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW The Longevity Consortium is mapping the biology of aging. We review the NIH-funded research aiming to delay chronic disease.The NIH-supported Longevity Consortium is a massive effort to understand the biology of aging to reduce risks of cancer, dementia, and frailty. We examine their five core focus areas, ranging from exceptional longevity cohorts to candidate drug screening. Dr. Nik Schork and Dr. George Murphy break down the current strategy for targeting age-related decline.This initiative represents a distinct pivot in geroscience research, moving beyond single-pathway hypotheses to look at systemic biological markers. We analyze the scope of these projects to see which are likely to yield clinical outcomes and which remain preliminary explorations. Understanding the biology of aging remains a complex challenge, but this consortium provides a structural framework for how we might eventually mitigate chronic disease. 🔑 KEYWORDS Longevity • Healthspan • Aging Biology • NIH • NIA • Longevity Consortium • Nik Schork • Centenarians • Human Cell Models • Geroscience 📌 KEY TAKEAWAYS ◆ Healthspan and lifespan are related goals, but improving a biological measurement is not the same as proving that people live longer. ◆ Exceptional longevity may reflect protective biology alongside disease-risk variants, as well as behavior and environmental exposures. ◆ The five projects connect discovery with functional testing. A genetic association still needs a biological explanation and follow-up experiments. ◆ Human cell models help isolate a signal; animal studies and human research test whether it matters in a more complex system. ◆ Public funding supports collaboration across disciplines and exploratory work that may not begin with a single commercial product. ◆ Shared aging mechanisms could offer opportunities to address multiple diseases. That is a research goal, not a claim that a proven universal treatment exists. ◆ A critical approach to evidence matters when evaluating claims about measuring or reversing biological age. 🎙️ THE REPROGRAM PERSPECTIVE Longevity Biology Without the Hype. The important question is not simply whether an intervention changes a marker, but whether it produces a meaningful, reproducible benefit for people. This conversation follows the research pathway; it does not present a finished anti-aging treatment.⏱️ CHAPTERS 00:00 Can we slow aging? 01:08 Meet Dr. Nik Schork 02:01 From philosophy to longevity science 03:53 What is the Longevity Consortium? 05:24 Healthspan versus lifespan 06:31 Why team science matters07:55 Project 1: Predicting human longevity 09:23 Project 2: Lessons from long-lived species 12:46 Project 3: Centenarians and resilience 14:50 Disease-risk genes and exceptional longevity 16:20 Project 4: From genes to candidate drugs 19:04 Project 5: Testing ideas in human cells 21:42 Connecting a discovery across the consortium 24:45 The challenge of proving human benefit 26:38 What public funding makes possible 29:12 Shared aging mechanisms and the public payoff 32:13 What success could look like 35:02 Lightning round: Can aging biology be modified? 36:12 Misconceptions about publicly funded science 37:24 How to evaluate longevity claims 39:13 How the science shapes Nik’s own health choices 41:50 Closing the conversation 42:48 The ReProgram takeaway 📝 SELECTED NOTES AND REFERENCES 1. Longevity Consortium overview. Official description of the research program and its integrated approach.https://www.longevityconsortium.org/overview/ 2. Longevity Consortium projects and resources. Explore the five projects and their leadership. https://www.longevityconsortium.org/ ▶ Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

🎬 EPISODE OVERVIEW Could the compound in magic mushrooms influence how we age? Psilocybin research is producing intriguing findings, but changing brain activity, treating depression and extending human life are very different claims.In Episode 27, Dr. George Murphy puts psilocybin through The ReProgram Scorecard. He examines experiments in human cells and aged mice, brain imaging and plasticity studies, inflammatory markers, and clinical research on depression.The episode also explores preliminary Parkinson’s and Alzheimer’s reports, why a change in a biomarker is not the same as preventing disease, and what it would take to establish a meaningful benefit for older adults.The verdict: psilocybin deserves serious investigation. The evidence discussed does not establish human life extension or dementia prevention. Its strongest clinical argument remains mental health treatment in carefully supervised settings. 🔑 KEYWORDS Psilocybin • Psilocin • Psychedelics • Longevity • Brain Plasticity • Depression • Inflammation • Cognitive Aging • ReProgram Scorecard 📌 KEY TAKEAWAYS • The longevity headline needs context. More cell divisions in a dish and improved mouse survival at a study endpoint do not demonstrate longer human life. • Brain changes are measurable. Plasticity and altered network coordination do not establish a universal neurotransmitter reset or a rejuvenated brain.• Inflammation findings vary. The marker, population and timing matter; sustained clinical benefit remains an open question. • Preliminary observations cannot establish dementia prevention. Small uncontrolled studies and an Alzheimer’s case report provide research questions, not proof of disease reversal. • Mental health benefits deserve their own assessment. Randomized evidence is encouraging, while durability, patient selection, support and adverse effects still matter. • Evidence grades are claim specific. A strong plasticity score cannot fill the evidence gap for dementia prevention or human life extension. 🎙️ THE REPROGRAM PERSPECTIVE Psilocybin’s potential is worth investigating. The next step is to establish which changes help, who benefits, how long benefits last, and what they cost in risk.Brain plasticity and network change: 4/5Mental health benefit in supervised treatment: 3/5Reducing inflammation: 2/5Preventing cognitive decline: 1/5Extending human lifespan: 1/5These are evidence grades, not treatment recommendations. They are not averaged into an overall score. The episode does not establish a longevity dosing regimen or justify self-directed use. ⏱️ CHAPTERS 00:00 Could psilocybin change how we age? 01:12 Five different claims 01:54 Cells mice and the longevity headline 03:19 What brain plasticity actually means 05:06 Human brain changes and study limitations 05:52 Neurotransmitters and the chemical reset claim 07:00 Inflammation signals and conflicting findings 09:00 Cognitive decline Parkinson's and Alzheimer's 10:58 Depression benefits durability and risks 11:59 The five part ReProgram Scorecard 13:26 What would change the evidence grades 14:03 Safety and the final verdict 📝 SELECTED NOTES AND REFERENCES1. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging. 2025. Cell and aged female mouse experiments behind the longevity discussion.https://doi.org/10.1038/s41514-025-00... 2. Psilocybin desynchronizes the human brain. Nature. 2024. Repeated imaging of brain network changes in seven healthy adults.https://doi.org/10.1038/s41586-024-07... 3. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell. Published online December 2025. Mouse research on activity-dependent plasticity.https://doi.org/10.1016/j.cell.2025.1... If you value longevity science without the hype, subscribe to The ReProgram. Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 26: GLP-1 Drugs for Longevity 🎬 EPISODE OVERVIEW A drug millions of people already take extended median lifespan by approximately 12% in older female mice. Does that change the case for GLP-1 drugs as longevity therapies?In this update, Dr. George Murphy reopens The ReProgram Scorecard to examine a new Nature study of late-life semaglutide treatment. He explores the survival findings, improvements in physical and cognitive performance, and the questions that determine how broadly we should interpret the results.How long did the control animals live? How much of the benefit came from eating less? What can a study conducted in females tell us about males—and ultimately humans?The episode also examines new research connecting calorie restriction with DNA mutation accumulation, the challenge of translating mouse biology into human outcomes, and the lessons from semaglutide’s Alzheimer’s trials.The updated assessment: stronger animal evidence and more compelling questions, while the overall grade remains B+. 🔑 KEYWORDS GLP-1 • Semaglutide • Ozempic • Wegovy • Longevity • Healthy Aging • Calorie Restriction • Somatic Mutations • Healthspan • ReProgram Scorecard 📌 KEY TAKEAWAYS • The survival finding deserves attention. Median lifespan increased from 742 to 834 days when semaglutide treatment began at 20 months of age and continued throughout life. • The calorie restriction question remains open. Selected functional outcomes were compared with matched calorie restriction; lifespan was not. • A benefit in females does not establish a female-specific effect. Males were not tested. • Historical controls provide context. They cannot replace the controls studied alongside treated animals; replication remains essential. • The DNA connection is a hypothesis. New calorie restriction research raises questions about mutation accumulation, but does not establish that semaglutide reduces somatic mutations. • Human outcomes still determine the grade. Strength, mobility, nutrition, cognition, and independence remain central to evaluating longevity interventions. 🎙️ THE REPROGRAM PERSPECTIVE This study strengthens the reason to investigate GLP-1 therapies in aging. It also sharpens the experiments we need next: replication, direct survival comparisons with calorie restriction, testing both sexes, and meaningful human outcomes.Mechanistic plausibility remains 4.5/5. Human evidence remains 3.5/5. The overall grade stays B+.My interest has increased. My standard of evidence has not changed. ⏱️ CHAPTERS 00:00 A 12% Lifespan Increase: What Does It Mean? 00:36 Revisiting GLP1 Therapies and Longevity 01:12 The New Nature Study 01:28 How Semaglutide Works 01:57 The Survival Result 03:10 The Importance of Starting Age in Treatment 03:57 The Control-Lifespan Debate 05:33 Sex Differences in Longevity Research 06:26 The Calorie Restriction Question 07:35 Calorie Restriction & DNA Mutations 09:01 Translating Mouse Findings to Humans 10:00 Lessons from the Alzheimer’s Trials 11:02 The Updated ReProgram Scorecard 📝 NOTES AND REFERENCES 1. Feng Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657:469–476. The central study discussed in this episode.https://www.nature.com/articles/s41586-026-10940-7 2. Grońska-Pęski M, et al. Caloric restriction modulates genome-wide somatic mutation in mice. Cell. 2026. The calorie restriction and mutation study discussed in the episode.https://doi.org/10.1016/j.cell.2026.08.013 3. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395. A landmark comparison showing that late-life intervention can extend lifespan in both sexes.https://www.nature.com/articles/nature08221 If you value longevity science without the hype, subscribe to The ReProgram. Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 25: 🩸 YOUR BLOOD MAY BE AGING BEFORE YOU ARE 🧠 Episode Overview Blood aging is often overlooked, but the hematopoietic stem cells inside your bone marrow carry a decades-long history.Your blood is not just a fluid; it is a continuously renewing organ system. As the stem cells that manufacture your blood cells age, they can shift immune composition and increase susceptibility to inflammation. This process is central to understanding how systemic aging actually unfolds, moving beyond simple protein panels or biological clocks to look at the cellular machinery that sustains you.We examine the reality of clonal hematopoiesis, known as CHIP, and why it acts as a risk marker rather than a diagnosis. By separating mechanism from marketing, we clarify what parabiosis experiments and plasma exchange can—and cannot—actually achieve in human biology. Understanding blood aging helps us prioritize evidence-based outcomes over the hype of rejuvenation.Subscribe to The ReProgram for scientist-led longevity biology breakdowns, and let us know in the comments if you want a deeper look at specific plasma-related interventions.#BloodAging #LongevityScience #HealthyAging #TheReProgram 🎙️ The ReProgram Perspective Blood aging forces us to rethink a familiar assumption. The cells circulating today may be new, but their factory - the hematopoietic stem-cell system and its marrow niche - has been shaped by decades of stress, inflammation, mutation, and repair.The biology is compelling because it connects systems that are often discussed separately: immunity, cancer risk, vascular inflammation, tissue repair, and aging. CHIP is a particularly powerful example. A mutation beginning in one stem cell can eventually influence enormous numbers of immune cells and potentially affect organs far beyond the bone marrow.But risk is not destiny, and mechanism is not treatment. CHIP should not be treated as leukemia, a mouse rejuvenation experiment should not be presented as a human anti-aging therapy, and a change in circulating proteins or an aging clock should not be confused with better function, fewer diseases, or longer life.The standard for a credible rejuvenation intervention should be transparent: disclose the intervention, pre-register the trial, define clinically meaningful outcomes, use appropriate controls, report adverse events, and publish the full results. Longevity science moves forward when fascinating biology is tested with standards strong enough to survive the hype around it. Office Artifact On the desk: GIANT MICROBES Blood Cells ⏱️ Chapters 00:00 The Blood Factory: Understanding Blood Cell Production 01:26 Aging Blood: Impacts on Health and Disease 02:38 The Role of Stem Cells in Blood Renewal 06:23 Immune Aging: The Complexity of Immune Responses 08:07 Clonal Hematopoiesis: A New Layer of Blood Aging 10:16 The Link Between Blood Aging and Cardiovascular Disease 12:52 Restoring Youth: Potential Strategies for Blood Rejuvenation 16:52 Parabiosis: The Young Blood Experiment 19:40 Plasma exchange: biology versus hype 21:15 Emerging Treatments: The One Generation Approach 25:09 Practical Takeaways: Managing Blood Health

Welcome to The ReProgram. Longevity science moves a lot slower than longevity marketing.The ReProgram explores the biology of aging, longevity drugs, regenerative medicine, nutrition, exercise, biotechnology, and the emerging science that may help us live longer, healthier lives. Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Understand Aging. Build Resilience. Extend Healthspan.

🎬 EPISODE OVERVIEW Every cell in your body contains essentially the same DNA, yet a neuron behaves nothing like a skin cell. So what actually gives a cell its identity — and how permanent is that identity?In this episode, Dr. George Murphy sits down with epigenetics and cellular reprogramming expert Dr. Jose Polo to explore how cells establish identity, how that identity can be rewritten, and what reprogramming really means for aging and rejuvenation.They discuss why cellular reprogramming is not the same thing as rejuvenation, Jose’s concept of “cell elasticity,” the danger of pushing a cell so far that it loses its identity, and the possibility of using targeted cell conversion as regenerative medicine. 👤 ABOUT THE GUEST Dr. Jose M. Polo is Director of the Adelaide Centre for Epigenetics in Australia. His research focuses on the transcriptional and epigenetic mechanisms that govern cell identity, pluripotency, cellular reprogramming, early development, and cancer. His laboratory has helped define the molecular sequence of somatic-cell reprogramming, developed strategies for direct cell-fate conversion, and pioneered human iBlastoid models of early embryonic development.Official profile: https://researchers.adelaide.edu.au/p... 🔑 KEYWORDS Epigenetics • Cellular Reprogramming • Cell Identity • Rejuvenation • Partial Reprogramming • Yamanaka Factors • Induced Pluripotent Stem Cells • Cell Elasticity • Epigenetic Clocks • Regenerative Medicine • iBlastoids • Human Embryo Models • Longevity • Aging 📌 KEY TAKEAWAYS • Cell identity is regulatory, not genetic. The same genome can produce radically different cell states depending on which programs are active. • Reprogramming is not the same as rejuvenation. Resetting cellular state may erase age-associated features, but that does not automatically mean restored function. • “Cell elasticity” may define the safe window for partial reprogramming. A cell can move away from its identity and return — until it crosses a point where that identity may no longer be recoverable. • Preserving identity is a central safety challenge. A cell that looks younger but loses its specialized function is not a successful rejuvenation strategy. • Cell-fate control could become medicine. Targeted reprogramming may one day convert resident cells into the cell types needed to repair damaged tissues. • iBlastoids demonstrate extraordinary human cell plasticity. But they are experimental models — not embryos — and their biological limits matter. 🎙️ THE REPROGRAM PERSPECTIVE Cellular reprogramming proves that cellular state is not fixed.But making an epigenetic clock move backward is not the same as making a cell healthier.The real goal of rejuvenation should be to restore function and resilience while preserving cell identity, tissue organization, and safety.In longevity science, the most meaningful endpoint is not simply whether a cell looks younger molecularly, but whether it behaves better biologically. ⏱️ CHAPTERS 02:27 Meet Dr. Jose Polo 05:34 What Makes a Cell a Neuron, Skin Cell, or Something Else? 08:15 What Is the Epigenome? 09:43 Reprogramming Is Not the Same as Rejuvenation 11:37 Does Epigenetic Change Cause Aging? 13:16 Cell Elasticity: How Far Can Identity Be Pushed? 14:39 The Danger Zone: Losing Cell Identity 16:48 Reprogramming Cells as Medicine 19:20 How Adult Cells Became Human Embryo Models 22:21 iBlastoids: What They Are — and What They Are Not 23:54 Is Aging a Failure of Cell Identity? 25:27 Can We Erase Bad Epigenetic Memory? 27:07 What We Still Do Not Understand About Reprogramming 📝 NOTES AND REFERENCES Liu X, Tan JP, Schroder J, et al. Modelling human blastocysts by reprogramming fibroblasts into iBlastoids. Nature. 2021;591:627-632.https://doi.org/10.1038/s41586-021-03... *If you value longevity science without the hype, subscribe to The ReProgram.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.*

🧠 EPISODE OVERVIEW Creatine is cheap, widely available, and backed by an unusually large body of human research. But its biology extends well beyond the gym. The creatine–phosphocreatine system helps cells rapidly regenerate ATP when energy demand rises—in both muscle and brain. In this episode, we examine the evidence for creatine and muscle preservation, cognition and brain resilience, kidney safety, dosing, and emerging high-dose brain protocols. And most importantly: does any of this make creatine a true longevity supplement? Creatine goes through The ReProgram Scorecard. Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype. 🔑 KEYWORDS Creatine • Creatine Monohydrate • Longevity • Healthspan • Muscle • Strength • Resistance Training • Brain Health • Cognition • ATP • Phosphocreatine • Kidney Health • Healthy Aging 🧠 KEY TAKEAWAYS Energy: Creatine helps buffer cellular energy by supporting rapid ATP regeneration. Muscle: The strongest evidence is for strength and performance. Combined with resistance training, creatine can improve strength and augment gains in lean tissue. Brain: Cognitive evidence is promising but less established. Benefits may be most relevant when the brain is under energetic stress. Alzheimer’s: Creatine is not proven to prevent or treat Alzheimer’s disease. Higher-dose brain protocols remain experimental. Kidneys: Safety data in healthy individuals are reassuring. Creatine can raise serum creatinine without necessarily indicating kidney damage. Dose: For most people, 3–5 g/day of creatine monohydrate is the conventional evidence-based approach. Loading is optional. Longevity: Healthspan evidence is not lifespan evidence. There is currently no randomized human evidence that creatine extends human lifespan. 🎙️ THE REPROGRAM PERSPECTIVE Creatine combines compelling biology, strong human evidence for specific outcomes, low cost, and reassuring safety—without proving that it slows human aging. Sometimes the most interesting intervention is not the newest or most expensive one. 📊 THE REPROGRAM SCORECARD: CREATINE ⚙️ Mechanistic Plausibility: A💪 Muscle & Performance Evidence: A🧠 Brain & Cognitive Evidence: B🛡️ Safety: A−💰 Cost & Accessibility: A+⏳ Direct Longevity Evidence: C 🏆 FINAL REPROGRAM GRADE: A− Verdict: Strong biology, unusually good human evidence for muscle and performance, reassuring safety, low cost, and an increasingly interesting brain story. The longevity claim itself remains unproven. ⏱️ CHAPTERS 00:00 Creatine: The Longevity Supplement Hiding in Plain Sight?01:58 Understanding Creatine: Mechanisms and Benefits03:56 Scorecard #1: Muscle & Performance07:07 Scorecard #2: The Brain & Cognition09:57 Creatine & Alzheimer’s Disease11:41 Scorecard #3: Safety & the Kidney Question14:39 Other Side Effects15:13 How Much Creatine Should You Take?16:33 What About Higher Doses for the Brain?17:46 The Final ReProgram Scorecard19:06 Final Thoughts: Creatine's Role in Longevity If you value longevity science without the hype, subscribe to The ReProgram. #Creatine #LongevityScience #HealthyAging #TheReProgram

🐾 EPISODE OVERVIEW This episode asks a deceptively simple question: Can we actually help our dogs and cats live longer, healthier lives?We explore why companion animals are unusually powerful models of aging, why “one dog year equals seven human years” is biologically wrong, what the Dog Aging Project is revealing, what pet owners can reasonably do today, and where emerging interventions like rapamycin, canine longevity drugs, AIM therapy, and gene therapy fit into the evidence. 🔑 KEYWORDS Pet longevity, dog aging, cat aging, healthspan, Dog Aging Project, rapamycin, TRIAD Trial, Loyal, feline kidney disease, AIM/CD5L, gene therapy, pet nutrition, body condition, muscle preservation, geroscience, comparative aging, healthy aging, veterinary medicine 💡 KEY TAKEAWAYS • Dogs and cats may be powerful real-world models of aging because they share our homes, environments, behaviors, and many naturally occurring diseases. • Dog years are not human years. Aging rates change throughout life and vary dramatically by breed and body size. • For most pets, the strongest longevity strategies today remain surprisingly conventional: appropriate body composition, good nutrition, movement, muscle preservation, dental care, pain management, preventive medicine, and early disease detection. • Rapamycin, dedicated canine longevity drugs, AIM therapy, and gene therapies are scientifically exciting—but they remain at different stages of experimental validation. • Healthspan matters more than lifespan at any cost. More time only matters if we preserve the experiences that make an animal recognizably itself. 🎙️ THE REPROGRAM PERSPECTIVE Pet longevity is a perfect example of why we need to separate mechanistic plausibility from meaningful outcomes.A supplement that changes a biomarker is not necessarily extending healthspan. An intervention that treats one age-related disease is not necessarily slowing aging throughout the entire organism. And an exciting mouse study is not a reason to start experimenting on your pet. Mechanism over marketing. Evidence over anecdotes. Healthspan over lifespan at any cost. OFFICE ARTIFACT On the desk: Tut, 3 year old Hairless Peterbald Sphinx: https://www.instagram.com/tutandbeebe.sphynx/ ⏱️ CHAPTERS 0:00 Can Our Pets Live Longer? 2:10 Welcome: The Science of Pet Longevity 3:52 Why Pets Are Living Aging Studies 7:58 The Myth of “Dog Years” 10:57 Inside the Dog Aging Project 14:19 What Pet Owners Can Do Right Now 16:56 Is There a Longevity Diet for Pets? 20:08 Oral Health and Preventative Care in Pets 21:40 Rapamycin and the TRIAD Trial 23:27 The First Canine Longevity Drugs? 24:30 AIM Therapy and Feline Kidney Disease 27:48 Gene Therapy for Aging-Related Disease 29:06 Purina and the Pet Longevity Industry 31:02 The ReProgram Pet Longevity Scorecard 33:54 Tut, Healthspan & Why More Time Matters

🧠 Episode Overview Mitochondria are known as the powerhouses of the cell—but energy production is only part of their story.In this episode of The ReProgram, Dr. George Murphy speaks with mitochondrial biologist Dr. Stefan Isaac about mitochondrial DNA, heteroplasmy, stress signaling, mitophagy, genome editing, and the possibility of transferring healthy mitochondria into damaged or aging cells.They also explore a central longevity paradox: more mitochondrial activity may not always be better. Long-lived organisms and centenarian-derived cells may preserve health through lower baseline activity, greater efficiency, and a stronger capacity to respond to stress.Could we replace aging mitochondria, repair mutant mitochondrial DNA, or generate rejuvenated mitochondria from reprogrammed cells? And would a young mitochondrion remain healthy inside an old cellular environment? 🔑 KeywordsStefan Isaac, mitochondria, mitochondrial aging, mitochondrial DNA, heteroplasmy, mitophagy, mitochondrial transfer, mitochondrial transplantation, genome editing, cellular reprogramming, centenarians, longevity, healthspan, ReProgram Podcast 🧠 Takeaways • Mitochondria regulate metabolism, stress signaling, and cell fate—not just energy production. • More mitochondrial activity is not necessarily better; longevity may depend on efficiency, adaptability, and recovery. • Exercise remains the strongest evidence-based strategy for supporting mitochondrial function. • Transplanted mitochondria remain dependent on the recipient cell’s nuclear genome and cellular environment. • Genome editing and selective removal of mutant mitochondrial DNA may transform future mitochondrial medicine. 🎙️ The ReProgram Perspective Resilience over raw output. Function over biomarkers. Mechanism over marketing.The longevity industry often assumes that more energy, more mitochondrial biogenesis, and more metabolic activity must be better. This episode challenges that assumption.A mitochondrion should not be judged only by ATP production, membrane potential, NAD levels, or quantity. The more important question is whether the cell can adapt to stress, remove damaged organelles, preserve function, and recover.Perhaps the goal is not to make mitochondria work harder. Perhaps the goal is to help them remain efficient, responsive, and resilient. Office Artifact: On the desk: Giant Microbes: Cell Organelles Chapters 03:35 Introducing Dr. Stefan Isaac 04:26 Beyond the Powerhouse 07:19 Mitochondrial Aging and DNA 10:58 Interventions and the Longevity Paradox 17:33 Mitochondrial Transfer and Transplantation 22:44 Reprogramming and Genome Editing 29:04 The Future—and What You Can Do Now

🧠 Episode Overview Metformin is inexpensive, widely prescribed, and supported by decades of clinical experience. It is also one of the most frequently discussed drugs in longevity medicine.But does metformin actually slow human aging?In this episode, Dr. George Murphy puts metformin through The ReProgram Scorecard, examining its biological mechanisms, human evidence, safety, accessibility, and likely value for people with—and without—metabolic disease.The central distinction is context. Metformin can delay diabetes in people at elevated metabolic risk, but evidence that it extends lifespan or broadly prevents age-related disease in metabolically healthy adults remains limited. Final ReProgram Grade: B− For healthy-adult longevity use: C+ 🔑 Keywords Metformin, metformin and longevity, biological aging, healthspan, diabetes prevention, insulin resistance, prediabetes, anti-aging drugs, longevity medicine, ReProgram Scorecard, Dr. George Murphy 🧠 Key Takeaways • Metformin is an established metabolic drug, not a proven anti-aging medication. • Its mechanisms intersect with energy sensing, glucose regulation, inflammation, mitochondrial biology, AMPK, and mTOR. • The strongest benefits are seen in people with diabetes, prediabetes, insulin resistance, or elevated metabolic risk. • Evidence that healthy, insulin-sensitive adults benefit from taking metformin for longevity is weak. • Long-term follow-up found that metformin prevented diabetes but did not significantly reduce all-cause, cardiovascular, or cancer mortality. • The key question is not whether metformin affects aging-related pathways. It is whether it improves meaningful outcomes in the right population. 🎙️ The ReProgram Perspective Mechanism over marketing.Evidence over anecdotes.Trade-offs over hype.Metformin deserves respect as a safe, inexpensive, and valuable metabolic medicine.But correcting abnormal metabolism is not necessarily the same as slowing aging in someone whose metabolism is already healthy.The stronger the underlying metabolic dysfunction, the greater the potential benefit. For healthy adults seeking a general longevity drug, the evidence is not yet compelling. 📊 The ReProgram Scorecard Mechanistic plausibility: 4 / 5 Human longevity evidence: 2.5 / 5 Likely benefit — metabolic-risk populations: 4 / 5 Likely benefit — metabolically healthy adults: 1.5 / 5 Safety and downside risk: 4 / 5 Cost and accessibility: 5 / 5 Longevity hype risk: Moderate–High Healthy-adult longevity use: C+ Final ReProgram Grade: B− Verdict: An excellent metabolic drug and plausible geroscience tool—but not a proven longevity drug for healthy people. Chapters 00:26 What Metformin Does 00:54 Is Metformin Really a Longevity Drug? 02:37 Understanding Metformin: Mechanisms and Uses 04:48 Evaluating Human Evidence for Metformin 07:46 Magnitude of Likely Benefits of Metformin 08:55 Safety and Potential Downsides of Metformin 10:54 Who May Benefit Most from Metformin 12:28 Cost, Accessibility, and Longevity Hype Risk 13:42 Final ReProgram Grade 📝 Notes and References 1. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes With Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002;346:393–403. Metformin reduced diabetes incidence by 31%, compared with 58% for intensive lifestyle intervention. PubMed: https://pubmed.ncbi.nlm.nih.gov/11832... 2. Lee CG, et al. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/34697... 3. Salive ME, et al. Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes. JAMA. 2026. DOI: 10.1001/jama.2026.8492. 4. Walton RG, et al. Metformin Blunts Muscle Hypertrophy in Response to Progressive Resistance Exercise Training in Older Adults: The MASTERS Trial. Aging Cell. 2019.

🧠 Episode Overview What if your age on paper is not the number that matters most?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Raghav Sehgal at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Sehgal discusses his work analyzing dozens of putative longevity interventions across epigenetic clocks, why DNA methylation data are uniquely useful for cross-study harmonization, and why some interventions may move aging biomarkers only in specific biological contexts.The central message: aging clocks are not magic answers, but they may become powerful instruments for separating longevity science from longevity marketing. 🔑 Keywords Raghav Sehgal, biological age, chronological age, aging clocks, epigenetic clocks, biomarkers of aging, longevity interventions, geroscience, AI and aging, artificial intelligence, rapamycin, metformin, hronic inflammation, lifestyle interventions, exercise, diet, supplements, follistatin gene therapy, clinical translation, precision longevity, ReProgram Podcast, Dr. George Murphy 🧠 Takeaways • Chronological age tells us how long we have been alive; biological age attempts to measure how fast health risk and physiological decline are progressing. • If aging cannot be quantified, it becomes difficult to test whether an intervention is actually modifying aging biology. • Epigenetic clocks are especially useful for large cross-study analyses because DNA methylation platforms are relatively standardized compared with many other omics technologies. • Dr. Sehgal describes a major harmonization effort across clinical trials and observational studies to ask which interventions move aging biomarkers. • Some surprising signals came from anti-retroviral therapy and inflammation-targeting drugs, raising questions about retrotransposons, immune activation, and chronic inflammation in aging. • Context matters: an intervention may shift aging biomarkers in one group, disease state, tissue, or organ system but not another. • Rapamycin remains promising in model organisms, but the human biomarker evidence is still more complicated and less definitive than the hype suggests. • AI may accelerate longevity science by cleaning messy datasets, mapping aging trajectories, and helping explain why a biological age score moved. • The future of longevity medicine will depend on better biomarkers, longitudinal data, careful interpretation, and avoiding one-size-fits-all claims. 🎙️ The ReProgram Perspective This episode is a reminder that longevity science is entering a measurement era. The key question is no longer only whether an intervention sounds plausible, works in mice, or has a compelling mechanism. The harder question is whether it measurably changes human aging biology in the right person, tissue, and context.The most important idea from this conversation may be that biological age is not a single magic number. It is a window into complexity. The promise of the field is not just to tell someone they are “younger” or “older” than expected. The promise is to understand why that signal is changing and what, if anything, can be done about it. Chapters 02:33 Introduction from the Systems Aging GRC 03:02 Biological Age vs Chronological Age 04:28 Testing 51 Longevity Interventions 06:20 Why Epigenetic Clocks? 08:12 Anti-Retroviral Therapy, Retrotransposons, and Aging 10:36 The Role of Inflammation in Aging 12:23 What Counts as a True Longevity Signature? 15:08 Rapamycin, Humans, and the Evidence Gap 16:31 Surprising Findings From the Study 18:19 Aging Clocks in the Clinic 19:47 AI, Big Data, and Longevity Science 22:32 Raghav’s Personal Health Transformation Notes Dr. Sehgal's Website: https://www.raghav-sehgal.com/ Dr. Sehgal's 51 Interventions Paper: https://www.biorxiv.org/content/10.1101/2024.10.22.619522v1.full TranslAGE: https://www.translage.io/

🧠 Episode Overview What if aging is shaped not only by what you eat, how much you exercise, or which genes you inherit — but also by when your body does things each day?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Mimi Shirasu-Hiza at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Shirasu-Hiza is a Professor of Genetics and Development at Columbia University and an international expert in circadian gene regulation, aging, and health.This conversation explores circadian rhythms as daily, approximately 24-hour oscillations in gene expression, tissue function, and behavior — and why disruption of those rhythms through shift work, jet lag, irregular sleep, or mistimed eating may affect metabolism, cardiovascular risk, obesity, cancer risk, and aging biology.A major focus is time-restricted eating: not simply eating less, but aligning eating and fasting with the body’s active and resting phases. Dr. Shirasu-Hiza discusses work in fruit flies showing that time-restricted eating can extend lifespan and preserve youthful oscillations in genes involved in metabolism, protein translation, immune defense, stress response, and other core biological programs. 🔑 Keywords Circadian rhythms, circadian clock, biological rhythms, time-restricted eating, intermittent fasting, caloric restriction, meal timing, fasting window, overnight fasting, metabolism, cardiovascular disease, obesity, cancer risk, aging biology, longevity science, geroscience, exercise, healthspan, resilience, ReProgram Podcast, Dr. George Murphy 🧠 Takeaways • Circadian rhythms are daily, approximately 24-hour oscillations in gene expression, tissue function, and behavior. • The circadian clock is not just about sleep; it helps coordinate transcription, metabolism, feeding, fasting, activity, tissue function, and recovery. • Circadian disruption is associated with cardiometabolic disease, obesity, and cancer risk, especially in shift workers, frequent travelers, and others whose activity occurs during the usual rest phase. • Time-restricted eating is different from caloric restriction. It focuses on when food is consumed, not necessarily how many calories are consumed. • Aging may involve loss of rhythmic gene expression. Time-restricted eating preserved youthful oscillations in genes linked to metabolism, protein translation, immune defense, defense response, and stress response. • Meal timing may help reset circadian rhythms during jet lag, suggesting that food can act as a timing cue for the body clock. 🎙️ The ReProgram Perspective This episode is a reminder that longevity science is not only about molecules, supplements, or single interventions. It is also about biological organization.Circadian biology reframes aging as a problem of timing. Genes, metabolism, immunity, tissue repair, behavior, feeding, and fasting are not static processes. They are coordinated across the day.Dr. Shirasu-Hiza’s work in flies is powerful because it shows that preserving youthful gene-expression rhythms may be linked to lifespan and health. But the translation to humans requires care. The takeaway is not that everyone should follow one rigid fasting window. The takeaway is that timing is biology — and maintaining rhythm may be one underappreciated part of resilience, recovery, and healthy aging. Chapters 00:00 Can Meal Timing Slow Aging? 02:16 Introduction from the Systems Aging GRC 03:08 What Are Circadian Rhythms? 03:46 Shift Work, Jet Lag, and Health Risk 04:30 Circadian Disruption and Cancer Risk 04:59 Time-Restricted Eating vs Intermittent Fasting 05:29 Eating Windows and Overnight Fasting 06:20 Why Fruit Flies Are Powerful Aging Models 07:17 The “Keep Me Young” Genes 08:47 Fasting, Foraging, and Exercise-Like Behavior 09:37 Can Drugs Mimic Circadian Benefits? 10:37 Meal Timing and Jet Lag 12:03 Calories, Diet Type, and Individual Differences 13:03 Closing Reflections

🧠 Episode Overview What if “biological age” as a single number is the wrong way to think about aging?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Rich Miller at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Miller is a Professor of Pathology at the University of Michigan and one of the leaders of the Interventions Testing Program, the gold standard for testing longevity interventions in genetically diverse mice.This conversation challenges some of the biggest assumptions in longevity science: biomarkers of aging, cellular senescence, the search for one cause of aging, and the idea that mouse lifespan results automatically translate into human recommendations.The central message:Aging is not one pathway, one biomarker, or one number.The real question is not simply what causes aging.The real question is what can postpone many forms of age-related decline at the same time. 🔑 Keywords Richard Miller, Interventions Testing Program, ITP, aging biology, longevity science, geroscience, biological age, biomarkers of aging, aging-rate indicators, anti-aging drugs, geroprotectors, rapamycin, acarbose, ergothioneine 🧠 Takeaways • Aging should not be reduced to one cause, one pathway, one biomarker, or one biological age number. • Rich Miller argues that the key question is not what causes aging, but what postpones many forms of age-related damage at once. • Lifespan is useful because it is definitive, but a true anti-aging drug should also delay multiple forms of functional decline. • Most proposed longevity interventions fail when tested rigorously. • Biomarkers of aging and aging-rate indicators are not the same thing. • A biomarker may change with age. An aging-rate indicator should tell us whether aging is moving faster or slower. • “Biological age” as a single number may hide important differences across tissues, systems, and disease risks. • Ergothioneine is intriguing in slow-aging mice, but it is not yet clear whether it is causal or simply a marker of a broader metabolic state. • Sex differences matter. Some interventions work in male mice but not female mice. • Rapamycin and acarbose are exciting in mice, but they are not proven human longevity drugs. • No drug has yet been proven to extend human lifespan by slowing aging itself. 🎙️ The ReProgram Perspective The ReProgram lens is simple:Mechanism over marketing.Outcomes over biomarkers.Trade-offs over hype.This episode is a reminder that longevity science needs both ambition and restraint.A compound that changes a biomarker has not necessarily slowed aging.A drug that extends lifespan in mice is not automatically safe or effective for humans.And a single “biological age” number may not capture the complexity of how real people age.Rich Miller’s message is not that aging biology is impossible.It is that the field has to be precise about what the data actually prove.The future of longevity science depends on rigorous testing, better endpoints, genetic diversity, sex-specific biology, and a clear distinction between promising mechanisms and proven outcomes. Chapters 00:00 Are There Really Biomarkers of Aging? 02:09 Dr. Rich Miller’s Origin Story 03:24 How His Views on Aging Changed 04:21 How Rich Miller Defines Aging and Its Complexities 05:48 The Interventions Testing Program (ITP) 07:31 What Is a True Anti-Aging Drug? 08:37 Longevity Signatures and Metabolites 10:33 The Role of Ergothionine in Aging 13:17 Biomarkers vs Aging-Rate Indicators 16:26 Sex Differences in Aging Research 19:11 The Importance of Genetically Diverse Models 22:09 Advocating for Aging Research 23:45 Aging Research and Cancer 25:19 Disease Silos in Science 27:11 Rich Miller’s Own Longevity Habits 29:51 The Risk of Rapamycin Self-Experimentation Notes The Interventions Testing Program (ITP): https://www.nia.nih.gov/research/dab/interventions-testing-program-itp Dr. Rich Miller Lab: https://www.richmillerlab.com/